HIV treatment and prevention on every 2026 Arkansas Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 12 stand-alone Part D plans in Arkansas cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
12 plans, cheapest premium first. Scroll sideways for all of them →
| Drug | Wellcare Classic$0.00/moS4802-073 | Wellcare Value Script$0.00/moS4802-153 | HealthSpring Assurance Rx$0.00/moS5617-225 | Humana Basic Rx Plan$0.00/moS5884-141 | Humana Value Rx Plan$0.00/moS5884-198 | BlueMedicare Value Rx$52.50/moS5795-003 | HealthSpring Extra Rx$54.50/moS5617-369 | AARP Medicare Rx Saver from UHC$65.10/moS5921-364 | SilverScript Choice$73.50/moS5601-038 | Humana Premier Rx Plan$92.40/moS5884-165 | AARP Medicare Rx Preferred from UHC$114.90/moS5921-400 | BlueMedicare Premier Rx$181.20/moS5795-002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biktarvybictegravir/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533% |
| Dovatodolutegravir and lamivudine | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533% |
| Triumeqabacavir/dolutegravir/lamivudine | Tier 426% | Tier 440% | Tier 429%QL 300/30d | Tier 434%QL 180/30d | Tier 433%QL 180/30d | Tier 434% | Tier 431%QL 300/30d | Tier 432%QL 180/30d | Tier 433% | Tier 450%QL 180/30d | Tier 429%QL 180/30d | Tier 434% |
| Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533% |
| Odefseyemtricitabine/rilpivirine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533% |
| Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533% |
| Julucadolutegravir and rilpivirine | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533% |
| Descovyemtricitabine and tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 533% |
| Truvadaemtricitabine and tenofovir disoproxil | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| emtricitabine-tenofovirgeneric Truvada | Tier 426%QL 30/30d | Tier 440%QL 30/30d | Tier 429%QL 30/30d | Tier 434%QL 30/30d | Tier 433%QL 30/30d | Tier 434% | Tier 431%QL 30/30d | Tier 432%QL 30/30d | Tier 433%QL 30/30d | Tier 450%QL 30/30d | Tier 429%QL 30/30d | Tier 434% |
| Tivicaydolutegravir | Tier 525% | Tier 525% | Tier 429%QL 180/30d | Tier 525%QL 60/30d | Tier 526%QL 60/30d | Tier 525% | Tier 431%QL 180/30d | Tier 525%QL 60/30d | Tier 525% | Tier 533%QL 60/30d | Tier 531%QL 60/30d | Tier 533% |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.